Catanzano Anthony, Phillips Michael, Dubrovskaya Yanina, Hutzler Lorraine, Bosco Joseph
NYU Hospital for Joint Diseases.
Iowa Orthop J. 2014;34:111-7.
The indications for vancomycin prophylaxis to prevent Methicillin-resistant Staphylococcus aureus (MRSA) surgical site infections are increasing. The recommended dose of vancomycin has traditionally been 1 gram intravenous. However, the increasing prevalence of obesity in our population coupled with increasing resistance of MRSA to vancomycin has resulted in recent recommendations for weight-based dosing of vancomycin at 15 mg/kg. We hypothesize that the standard one gram dose of vancomycin is inadequate to meet the recently recommended dosage of 15 mg/kg.
We performed a retrospective chart review on 216 patients who were screened positive for MRSA prior to undergoing elective total joint or spine surgeries between January 2009 to January 2012. All patients were given 1 gram of vancomycin within an hour prior to surgical incision as prophylaxis. Using the revised dosing protocol of 15 mg/kg of body weight for vancomycin, proper dosage was calculated for each patient. These values were then compared to the 1 gram dose given to the patients at time of surgery. Patients were assessed as either underdosed (a calculated weight-based dose >1 gram) or overdosed (a calculated weight-based dose <1 gram). Additionally, we used actual case times and pharmacokinetic equations to determine the vancomycin (VAN) levels at the end of the procedures.
Out of 216 patients who tested positive for MRSA, 149 patients (69%) were determined to be underdosed and 22 patients (10%) patients were determined to be overdosed. The predicted VAN level at the end of procedure was <15 mg/L in 60% of patients with 1 gram dose compared to 12% (p=0.0005) with weight base dose. Six patients developed post-operative MRSA surgical site infections (SSI). Of these six patients; four had strains of MRSA with vancomycin minimum inhibitory concentration of >1.0 mg/L. Based on 1 g dosing, 5/6 patients with MRSA positive SSIs had wound closure levels of <15 mg/L and all six were <20 mg/L.
In settings such as hospitals, where the risk for resistant bacteria, especially MRSA, is high, it is becoming increasingly important to accurately dose patients who require vancomycin. In order to avoid incorrect dosing of vancomycin health care providers must use weight-based dosing.
万古霉素预防耐甲氧西林金黄色葡萄球菌(MRSA)手术部位感染的适应证正在增加。传统上推荐的万古霉素剂量为静脉注射1克。然而,我国肥胖人群的患病率不断上升,加之MRSA对万古霉素的耐药性增强,导致最近建议根据体重给药,剂量为15毫克/千克。我们推测,标准的1克万古霉素剂量不足以达到最近推荐的15毫克/千克的剂量。
我们对2009年1月至2012年1月期间接受择期全关节或脊柱手术前MRSA筛查呈阳性的216例患者进行了回顾性病历审查。所有患者在手术切口前1小时内给予1克万古霉素作为预防用药。使用修订后的万古霉素体重给药方案(15毫克/千克),为每位患者计算合适的剂量。然后将这些值与手术时给予患者的1克剂量进行比较。患者被评估为剂量不足(计算出的基于体重的剂量>1克)或剂量过量(计算出的基于体重的剂量<1克)。此外,我们使用实际病例时间和药代动力学方程来确定手术结束时的万古霉素(VAN)水平。
在216例MRSA检测呈阳性的患者中,149例(69%)被确定为剂量不足,22例(10%)被确定为剂量过量。1克剂量组60%的患者手术结束时预测的VAN水平<15毫克/升,而基于体重剂量组为12%(p = 0.0005)。6例患者发生术后MRSA手术部位感染(SSI)。在这6例患者中,4例的MRSA菌株万古霉素最低抑菌浓度>1.0毫克/升。基于1克给药,5/6例MRSA阳性SSI患者的伤口闭合时VAN水平<15毫克/升,所有6例均<20毫克/升。
在医院等耐药菌尤其是MRSA风险较高的环境中,准确计算需要万古霉素治疗患者的剂量变得越来越重要。为避免万古霉素给药错误,医护人员必须采用基于体重的给药方法。